Coherus Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Coherus BioSciences
CHRS Stock  USD 2.22  0.05  2.30%   
Coherus BioSciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Coherus BioSciences' valuation are provided below:
Gross Profit
156.4 M
Profit Margin
0.558
Market Capitalization
268.3 M
Enterprise Value Revenue
0.4226
Revenue
277.7 M
There are over one hundred nineteen available fundamental signals for Coherus BioSciences, which can be analyzed over time and compared to other ratios. All traders should validate Coherus BioSciences' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to gain to about 504.5 M in 2026, whereas Market Cap is likely to drop slightly above 135.2 M in 2026.

Coherus BioSciences Total Revenue

182.15 Million

Check Coherus BioSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coherus BioSciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 16.9 M or Selling General Administrative of 102.8 M, as well as many indicators such as Price To Sales Ratio of 0.65, Dividend Yield of 0.0 or Days Sales Outstanding of 93.4. Coherus financial statements analysis is a perfect complement when working with Coherus BioSciences Valuation or Volatility modules.
  
Build AI portfolio with Coherus Stock
Check out the analysis of Coherus BioSciences Correlation against competitors.
For more information on how to buy Coherus Stock please use our How to Invest in Coherus BioSciences guide.

Coherus BioSciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding138.7 M132.1 M60 M
Slightly volatile
Total Assets372.6 M515.8 M314.4 M
Slightly volatile
Short and Long Term Debt Total256 M310.4 M196 M
Slightly volatile
Other Current Liabilities305.3 M290.8 M105.4 M
Slightly volatile
Total Current Liabilities341.7 M325.4 M130 M
Slightly volatile
Other Liabilities3.8 M4 M25.3 M
Pretty Stable
Property Plant And Equipment Net3.1 M3.3 M6.4 M
Pretty Stable
Accounts Payable19.6 M32.7 M17.2 M
Slightly volatile
Cash179 M144.9 M145.2 M
Slightly volatile
Non Current Assets Total64 M123 M55.7 M
Slightly volatile
Non Currrent Assets Other42.1 M58 M35.2 M
Slightly volatile
Other Assets77.5 M73.8 M29.7 M
Slightly volatile
Cash And Short Term Investments191.1 M144.9 M154.3 M
Slightly volatile
Common Stock Total Equity5.6 K9.2 K5.2 K
Slightly volatile
Liabilities And Stockholders Equity372.6 M515.8 M314.4 M
Slightly volatile
Non Current Liabilities Total272 M342.2 M225.9 M
Slightly volatile
Other Current Assets21.4 M26.6 M18.9 M
Slightly volatile
Other Stockholder Equity861.1 M1.6 B745.4 M
Slightly volatile
Total Liabilities367.6 M667.6 M318.5 M
Slightly volatile
Property Plant And Equipment Gross15.9 M27.4 M13.8 M
Slightly volatile
Total Current Assets308.5 M392.8 M258.7 M
Slightly volatile
Short Term Debt1.4 M1.5 M4 M
Pretty Stable
Common Stock14.5 K13.8 K6.4 K
Slightly volatile
Property Plant Equipment102.7 M97.8 M37.4 M
Slightly volatile
Capital Surpluse900.6 M1.4 B769.4 M
Slightly volatile
Short and Long Term Debt199.2 K209.7 K614.1 K
Slightly volatile
Non Current Liabilities Other52.8 M32.5 M42.9 M
Pretty Stable
Intangible Assets64.8 M61.7 M16.9 M
Slightly volatile
Long Term Debt Total230.6 M259.4 M177.1 M
Slightly volatile
Net Invested Capital145.2 M152.9 M209 M
Slightly volatile
Net Working Capital64 M67.4 M174.6 M
Pretty Stable
Capital Stock9.3 K13.8 K8.1 K
Slightly volatile
Capital Lease Obligations7 M4.5 M9.2 M
Slightly volatile

Coherus BioSciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.2 M6.1 M2.8 M
Slightly volatile
Interest Expense16.9 M31.2 M14.8 M
Slightly volatile
Selling General Administrative102.8 M160.5 M87.6 M
Slightly volatile
Total Revenue182.2 M307 M155.6 M
Slightly volatile
Other Operating Expenses307.4 M435.4 M262.2 M
Slightly volatile
Research Development159.6 M107.3 M130.8 M
Slightly volatile
Cost Of Revenue104.4 M135.2 M90.8 M
Pretty Stable
Total Operating Expenses268.6 M300.2 M224.9 M
Slightly volatile
Interest Income21.3 M20.2 M10.3 M
Slightly volatile
Reconciled Depreciation4 M6.1 M3.7 M
Slightly volatile
Selling And Marketing Expenses8.2 M12.5 M5.6 M
Slightly volatile

Coherus BioSciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation31.6 M32 M25.8 M
Slightly volatile
Begin Period Cash Flow169.3 M118.8 M135.5 M
Slightly volatile
Depreciation6.4 M6.1 M2.8 M
Slightly volatile
End Period Cash Flow179.2 M145.2 M145.4 M
Slightly volatile
Change To Netincome68.6 M95.4 M59.5 M
Slightly volatile
Issuance Of Capital Stock1.2 M1.3 M64 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.650.6851.3258
Pretty Stable
Days Sales Outstanding93.4151111
Slightly volatile
Stock Based Compensation To Revenue0.110.122.8891
Very volatile
Capex To Depreciation0.08240.08682.5954
Slightly volatile
Payables Turnover6.444.756.1864
Slightly volatile
Sales General And Administrative To Revenue0.570.67.3088
Very volatile
Research And Ddevelopement To Revenue0.380.415.1067
Pretty Stable
Capex To Revenue0.00120.00130.3999
Slightly volatile
Cash Per Share1.21.264.0993
Slightly volatile
Days Payables Outstanding75.5479.52191
Very volatile
Intangibles To Total Assets0.110.11960.0396
Slightly volatile
Current Ratio2.061.092.4209
Very volatile
Receivables Turnover2.382.5111.4858
Pretty Stable
Capex Per Share0.00330.00350.1779
Slightly volatile
Revenue Per Share2.092.12.3199
Slightly volatile
Interest Debt Per Share2.352.332.6608
Slightly volatile
Debt To Assets0.460.540.504
Slightly volatile
Graham Number7.7711.528.7936
Slightly volatile
Days Of Payables Outstanding75.5479.52191
Very volatile
Long Term Debt To Capitalization0.921.791.0627
Slightly volatile
Quick Ratio0.820.862.1125
Very volatile
Net Income Per E B T1.091.151.0098
Slightly volatile
Cash Ratio0.490.511.6394
Pretty Stable
Days Of Sales Outstanding93.4151111
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.091.151.0166
Pretty Stable
Fixed Asset Turnover88.9284.6928.5577
Slightly volatile
Debt Ratio0.460.540.504
Slightly volatile
Price Sales Ratio0.650.6851.3258
Pretty Stable
Asset Turnover0.30.540.3453
Slightly volatile

Coherus BioSciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap135.2 M142.3 M465.2 M
Pretty Stable

Coherus Fundamental Market Drivers

Forward Price Earnings41.1523
Cash And Short Term Investments126 M

Coherus Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Coherus BioSciences Financial Statements

Coherus BioSciences shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Coherus BioSciences investors may analyze each financial statement separately, they are all interrelated. The changes in Coherus BioSciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Coherus BioSciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-77.7 M-73.8 M
Total Revenue307 M182.2 M
Cost Of Revenue135.2 M104.4 M
Stock Based Compensation To Revenue 0.12  0.11 
Sales General And Administrative To Revenue 0.60  0.57 
Research And Ddevelopement To Revenue 0.40  0.38 
Revenue Per Share 2.10  2.09 
Ebit Per Revenue(0.38)(0.40)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Coherus Stock Analysis

When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY